- Press Release -

Rockville, Md. The global recombinant protein market is set to reach nearly US$ 460 Mn by 2022 on moderate growth, according to Fact.MR. Produced through genetic and cell engineering, recombinant proteins sit at the leading edge of biotechnology production, and the field is shifting from bulk production toward post-production techniques that improve delivery and stability.

Basic research is the largest application, growth factors lead by product, and academic and research institutes account for most use. North America is the dominant region, while biopharmaceutical companies and chemokines are the fastest-growing pockets.

Applications, Products and End Users

Basic research remains the largest application at roughly US$ 270 Mn by 2022, while toxicity screening and drug discovery and development grow fastest and forensic testing grows slowest. By product, growth factors lead while chemokines expand quickest. Among end users, academic and research institutes are the most lucrative at over a third of revenue, with biopharmaceutical companies the fastest-growing.

North America stays dominant at about US$ 150 Mn by 2022, Europe ranks second, and the Middle East and Africa grows sluggishly.

Safety and Speed Drive Demand

The market runs on clinical advantage. Recombinant proteins offer higher safety than small molecules and shorter clinical trial periods, which improves patient protection and gives makers longer exclusive sales windows. They target diseases from haemophilia and cardiovascular and endocrine conditions to viral disease and cancer, though technical and financial barriers keep the technology expensive and replication challenging.

Suppliers and Their Playbook

The field brings together life-science and reagent companies.

• Thermo Fisher Scientific, Inc., Sigma Aldrich, Merck Millipore Limited, GenScript Corporation, Crown Bioscience, Inc., PerkinElmer, Inc., BPS Bioscience Inc., Bio-Rad Laboratories, Inc., A.M.S. Biotechnology (Europe) Limited, and Abcam plc are among the key players in the report.

Reading the Market for Decisions

For suppliers, growth favours research-oriented products and biopharmaceutical customers. Investors get a small, specialised market with steady demand. Procurement and lab teams can plan around basic research carrying volume, academic institutes leading use, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global recombinant protein market for the 2017 to 2022 forecast period, with segmentation by product, application, end user and region. It sizes each segment, maps the competitive field, and weighs the clinical and research forces shaping demand. Further detail is available in the recombinant protein market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.